JP Patent

JP6203182B2 — （ｓ）−エチル２−アミノ−３−（４−（２−アミノ−６−（（ｒ）−１−（４−クロロ−２−（３−メチル−１ｈ−ピラゾール−１−イル）フェニル）−２，２，２−トリフルオロエトキシ）ピリミジン−４−イル）フェニル）プロパノエートの固形剤

Assigned to レクシコン ファーマシューティカルズ インコーポレイテッド · Expires 2017-09-27 · 9y expired

What this patent protects

Patent listed against infigratinib-phosphate.

Drugs covered by this patent

Patent Metadata

Patent number
JP6203182B2
Jurisdiction
JP
Classification
—
Expires
2017-09-27
Drug substance claim
No
Drug product claim
No
Assignee
レクシコン ファーマシューティカルズ インコーポレイテッド
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.